Novo Nordisk Deploys Tiered Pricing and Weekly Insulin to Broaden GLP-1 Reach as Medicare Uptake Lags

Medicare Part D prescriptions for Wegovy surged nearly 600 percent within six months of the FDA’s March 2024 cardiovascular risk label expansion, jumping from roughly 367,000 to over 868,000. Yet that headline number masks a stubborn reality: fewer than 1 percent of the 3.6 million eligible Medicare beneficiaries actually filled the drug. High co-pays and hesitant insurance plans continue to throttle demand, even as a temporary pilot program called the “Medicare GLP-1 Bridge” – set to expire in 2027 – tries to ease the bottleneck. Novo Nordisk’s latest strategic gambit, a tiered pricing model for its new oral Wegovy tablet, is designed to crack that logjam wide open.

The oral formulation launched this week across more than 70,000 US pharmacies, including CVS and Costco, and via telemedicine platforms such as Ro, LifeMD, Weight Watchers, and even the TrumpRx portal at $149 per month. The entry dose of 1.5 milligrams costs $5 a day – roughly $149 monthly. The 4-milligram dose holds at that same $149 price until April 15 before rising to $199, while the highest available strength will cap out at $299 per month. Patients with private insurance may see out-of-pocket costs as low as $25. CVS Health, meanwhile, has expanded its GLP-1 support: eligible Medicare beneficiaries now pay $50 monthly, with an additional $49 for a companion telemedicine weight-management program. Separately, the UK regulator has already greenlit the daily pill, giving the stock an extra tailwind.

On the diabetes front, Novo Nordisk planted its flag in India on July 10 with the launch of Awiqli, the world’s first weekly basal insulin injection. India is home to roughly 101 million diabetes patients, and the new regimen cuts annual injections from 365 to just 52, at a cost of around 261 rupees per week. The ONWARDS clinical program, which enrolled more than 4,000 adults, showed superior HbA1c reduction compared with daily glargine. The move complements the oral Wegovy rollout and gives the Danish pharma giant a dual offensive against Eli Lilly in two of the fastest-growing therapeutic segments.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

CEO Mike Doustdar is simultaneously retooling the pipeline strategy. After disappointing Phase 3 data for CagriSema – a GLP-1/amylin combination that fell short of expectations relative to Lilly’s Zepbound – he has signaled a shift toward acquisitions rather than relying solely on internal R&D. CagriSema could still win approval by the end of 2026, and development of another amylin candidate, Zenagamtide, is being accelerated. Novo Nordisk is also collaborating with Vivani Medical on a once- or twice-yearly semaglutide implant called NPM-139, with a Phase 1 study expected to begin in mid-2026.

On the bourse, shares have staged a meaningful recovery from the March trough of €30.25, but remain far from the 52-week high of €61.20 set last July. The stock recently traded at €43.04, up 0.40 percent from the previous close of €42.87, giving it a market capitalization of €189.31 billion. Over the past month the equity has gained 16.03 percent, yet it still sits 3.67 percent lower year-to-date and 29.67 percent lower over twelve months. Technical indicators paint a cautiously bullish picture: the price is comfortably above both the 50-day moving average of €39.51 and the 200-day line of €40.60, with a relative strength index of 64.7 – suggesting buying momentum that has not yet become overheated. The analyst consensus, according to MarketBeat, remains a “Hold” with a price target of $65.56, and the trailing price-to-earnings ratio stands at roughly 11.5.

Still, headwinds persist beyond the competitive pressure from Lilly. A cybersecurity incident with potential unauthorized data access recently generated negative headlines, and Reuters has reported that some US employers may drop GLP-1 coverage from insurance plans as early as 2027. In Canada, a reformulated Rybelsus with lower dose strengths has been introduced. Meanwhile, institutional sentiment appears divided: Private Advisor Group and Azzad Asset Management adjusted their Novo Nordisk positions in opposite directions during the first quarter of 2026, reflecting the uncertainty that continues to surround the stock despite the flurry of pipeline and commercial initiatives.